Research Article

Drug Utilization Evaluation of Colistin: A Retrospective Study


Background: Colistin, is used as the last treatment line for infections concluded from multiple drug-resistant gram-negative microorganisms. Increased consumption of colistin leads to resistance to this antibiotic in many countries. This study investigated the usage pattern of colistin administration in a selected hospital in Iran.
Methods: This study was conducted in a selected hospital in Ahvaz. Inclusion criteria were all patients who received colistin during this time according to the health information system. Patients who were received less than three doses of colistin were excluded from the study. Prescription of colistin in all patients was evaluated according to the protocol extracted from the last version of Lexicomp written by Wolters Kluwer. The descriptive and analytical statistics were carried out by the R software.
Results: Among 27 patients who received colistin, pneumonia (15%) and respiratory distress syndrome (15%) were the main diagnoses. Colistin administration was based on the microbiological culture data in 70% of cases. Considering the involved microorganism, most cases were Acinetobacter spp., followed by Klebsiella spp. Loading dose was prescribed for seven (26%) patients. In only five (19%) cases, colistin dosing, including loading dose, maintenance dose, and the interval of colistin administration, was appropriate during the study time. Increasing in serum creatinine was seen in two (7.4%) patients. In 29.4% of patients, the combination of colistin and carbapenems was observed.
Conclusion: Given the lack of appropriate dose adjustment of colistin that may lead to incidence of resistance and adverse effect, applying of the specialist clinical pharmacist will be suggested.

[1] Truter I. A review of drug utilization studies and methodologies. Jordan journal of pharmaceutical sciences. 2008;1(2):91-103.
[2] Aslam B, Wang W, Arshad MI, Khurshid M, Muzammil S, Rasool MH, et al. Antibiotic resistance: a rundown of a global crisis. Infect Drug Resist. 2018; 11:1645.
[3] Biswas S, Brunel J-M, Dubus J-C, Reynaud-Gaubert M, Rolain J-M. Colistin: an update on the antibiotic of the 21st century. Expert Rev Anti Infect Ther. 2012;10(8):917-34.
[4] Nation RL, Li J. Colistin in the 21st century. Curr Opin Infect Dis. 2009; 22(6):535-43.
[5] Spapen H, Jacobs R, Van Gorp V, Troubleyn J, Honoré PM. Renal and neurological side effects of colistin in critically ill patients. Ann Intensive Care. 2011;1(1):1-7.
[6] Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis. 2006; 6(9):589-601.
[7] Bialvaei AZ, Samadi Kafil H. Colistin, mechanisms and prevalence of resistance. Curr Med Res Opin. 2015; 31(4):707-21.
[8] Karimzadeh I, Sadeghimanesh N, Mirzaee M, Sagheb MM. Evaluating the resistance pattern of gram-negative bacteria during three years at the nephrology ward of a referral hospital in southwest of Iran. J Nephropathol. 2017; 6(3): 210-9.
[9] Safari M, Saidijam M, Bahador A, Jafari R, Alikhani MY. High prevalence of multidrug resistance and metallo-beta-lactamase (MbetaL) producing Acinetobacter baumannii isolated from patients in ICU wards, Hamadan, Iran. J Res Health Sci. 2013; 13(2):162-7.
[10] Vakili B, Fazeli H, Shoaei P, Yaran M, Ataei B, Khorvash F, et al. Detection of colistin sensitivity in clinical isolates of Acinetobacter baumannii in Iran. J Res Med Sci. 2014;19(Suppl 1):S67-70.
[11] Shahcheraghi F, Abbasalipour M, Feizabadi M, Ebrahimipour G, Akbari N. Isolation and genetic characterization of metallo-β-lactamase and carbapenamase producing strains of Acinetobacter baumannii from patients at Tehran hospitals. Iran J Microbiol. 2011; 3(2):68-74.
[12] Kluwer W. Lexicomp: Evidence-Based Drug Treatment Information [Available from:
[13] Eliassy S, Rahimi PE, Mohammadpour AH, Naderi H. The Pattern of In-patient Colistin Prescription for Patients Admitted to Imam Reza Hospital at Mashhad. Medical J Mashhad. 2020; 63(2): 2272-91.
[14] Rezaie N, Farasatinasab M, Vaiszadeh N, Jamshidi M, Ranjbar M, Yasin Z, et al. Colistin Utilization Evaluation in a Major Teaching Hospital in Iran. J Pharm Care. 2018;6(1-2):19-22.
[15] Vazin A, Karimzadeh I, Zand A, Hatami-Mazinani N, Firouzabadi D. Evaluating adherence of health-care team to standard guideline of colistin use at intensive care units of a referral hospital in Shiraz, Southwest of Iran. Adv Pharm Bull. 2017;7(3):391.
[16] Kift EV, Maartens G, Bamford C. Systematic review of the evidence for rational dosing of colistin. S Afr Med J. 2014; 104(3):183-6.
[17] Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017; 43(3):304-77.
[18] Rhee C. Using Procalcitonin to Guide Antibiotic Therapy. Open Forum Infect Dis. 2016; 4(1):ofw249.
[19] Ordooei Javan A, Shokouhi S, Sahraei Z. A review on colistin nephrotoxicity. Eur J Clin Pharmacol. 2015; 71(7):801-10.
[20] Pogue JM, Lee J, Marchaim D, Yee V, Zhao JJ, Chopra T, et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis. 2011; 53(9):879-84.
[21] Cai Y, Chai D, Wang R, Liang B, Bai N. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother. 2012; 67(7): 1607-15.
[22] Rodriguez CH, De Ambrosio A, Bajuk M, Spinozzi M, Nastro M, Bombicino K, et al. In vitro antimicrobials activity against endemic Acinetobacter baumannii multiresistant clones. J Infect Dev Ctries. 2010; 4(03):164-7.
[23] Yahav D, Farbman L, Leibovici L, Paul M. Colistin: new lessons on an old antibiotic. Clin Microbiol Infect. 2012; 18(1):18-29.
[24] Durante-Mangoni E, Signoriello G, Andini R, Mattei A, De Cristoforo M, Murino P, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis. 2013;57(3):349-58.
[25] Global tuberculosis report 2019: World Health Organization; [Available from:
[26] Daoud Z, Mansour N, Masri K. Synergistic combination of carbapenems and colistin against P. aeruginosa and A. baumannii. Open Journal of Medical Microbiology. 2013;2013.
[27] Marie MA, Krishnappa LG, Alzahrani AJ, Mubaraki MA, Alyousef AA. A prospective evaluation of synergistic effect of sulbactam and tazobactam combination with meropenem or colistin against multidrug resistant Acinetobacter baumannii. Bosn J Basic Med Sci. 2015; 15(4):24-9.
[28] Batirel A, Balkan I, Karabay O, Agalar C, Akalin S, Alici O, et al. Comparison of colistin–carbapenem, colistin–sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections. Eur J Clin Microbiol Infect Dis. 2014; 33(8): 1311-22.
[29] Miller AD, Ball AM, Bookstaver PB, Dornblaser EK, Bennett CL. Epileptogenic potential of carbapenem agents: mechanism of action, seizure rates, and clinical considerations. Pharmacotherapy. 2011; 31(4):408-23.
IssueVol 8 No 1 (2022): Winter QRcode
SectionResearch Article(s)
Colistin Drug Utilization Evaluation (DUE) Teaching hospital Antibiotic resistance

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
Ghasri E, Hematian F, Ganji R, Izadpanah M. Drug Utilization Evaluation of Colistin: A Retrospective Study. Arch Anesth & Crit Care. 2022;8(1):47-52.